|
| |
Ming Tan, M.D., Ph.D.
Assistant Professor of Oncologic Sciences
Vincent F. Kilborn, Jr. Cancer Research Scholar
Office:
USA Mitchell Cancer Institute
1660 Springhill Avenue
Mobile, AL. 36604
Telephone: (251) 460-6993
Fax: (251) 460-6994
mtan@usouthal.edu
|
Professional Profile
Research Interests:
-Metabolism and cancer
-MicroRNA and cancer
-Cancer metastasis
-Therapeutic resistance
-Targeted cancer therapy
Honors and Academic Achievements:
-Vincent F. Kilborn, Jr. Cancer Research Scholar, USA Mitchell Cancer Institute, 2007.
-Second Prize Winner, Alexander Y-M Wang Memorial Awards, SCBA Annual Scientific Symposium Oral Competition, 2003.
-Sowell-Huggins Scholar for Excellence in Cancer Research, The University of Texas M.D. Anderson Cancer Center and Health Sciences Center at Houston, 2000.
-Fellowship Award, U.S. Department of Defense Breast Cancer Research Program Fellowship, 1997.
-Research Award for Outstanding Young Scientist, Science and Technology Association of Sichuan Province, China, 1991.
Education:
-Ph.D., The University of Texas M.D. Anderson Cancer Center and Health Science Center at Houston, Texas. (2000)
-M.D., West China University of Medical Sciences, Chengdu, China. (1985)
Professional Appointments:
-Member, USA Mitchell Cancer Institute, 2007-present
-Assistant Professor, Cell Biology & Neuroscience, University of South Alabama, 2007-present
Service:
-Scientist Reviewer, US Department of Defense, Breast Cancer Research Program, 2009
-Reviewer for Cancer Research, Oncogene, Molecular Cancer Therapeutics, and Molecular Cancer Research, 2005-present
Scientific Focus:
Dr. Tan is an assistant professor of Oncologic Sciences and Vincent F. Kilborn, Jr. Cancer Research Scholar at the Mitchell Cancer Institute. His laboratory focuses on the molecular mechanisms of tumor progression, metastasis, and therapeutic resistance of human breast cancer, melanoma, and other cancer types.
Currently Dr. Tan’s lab is studying growth factor receptors, such as HER-2/ErbB2, and transcription factors, such as HSF1, in mediating cancer metabolism, signal transduction, apoptosis, metastasis, and resistance to therapeutic agents. Another emphasis of his study is on the deregulation of microRNA in cancer progression and therapeutic resistance.
The ultimate goal of Dr. Tan’s research is to translate the knowledge acquired in the laboratory into future novel therapeutics.
Selected Publications:
1. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu DH, Fodstad O, and Tan M. (2009) Upregulation of LDH-A by ErbB2 through HSF1 promotes breast cancer cell glycolysis and growth. Oncogene (online publication 10 August 2009; doi: 10.1038/onc.2009.229)
2. Tan M, Lan KH, Yao J, Lu CH, Sun MH, Neal CL, Lu J, and Yu D. (2006) Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting STAT3-blocking peptide. Cancer Res 66: 3764-3772.
3. Tan M, Li P, Sun MH, and Yu D. (2006) Activation of PKC-alpha By ErbB2 though Src promotes breast cancer cell invasion that can be blocked by combined treatment of PKC-alpha and Src inhibitors. Oncogene 25: 3286–3295.
4. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, and Yu D. (2004) PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-121. Featured in the News or Commentaries: Nature, N Engl J Med, Cancer Cell).
5. Tan M, Jing T, Lee S, Lan KH, Li P, Nagata Y, Liu J, Arlinghaus R, Hung MC, and Yu D. (2002) Direct phosphorylation on tyrosine-15 of p34Cdc2 by ErbB2 receptor tyrosine kinase inhibits p34Cdc2 activation. Molecular Cell 9: 993-1004 (featured on the journal cover).
Patents:
-Yu D, Yao J, Lan KH, Tan M et al. Novel strategy for targeting therapeutics in breast cancer therapy. United States, IDR filed.
Research Support:
-The Vincent F. Kilborn, Jr. Cancer Research Foundation
-The Norwegian Radium Legater Award
|
|
|
| |
|